409 related articles for article (PubMed ID: 29495487)
21. Structural Basis of Dot1L Stimulation by Histone H2B Lysine 120 Ubiquitination.
Valencia-Sánchez MI; De Ioannes P; Wang M; Vasilyev N; Chen R; Nudler E; Armache JP; Armache KJ
Mol Cell; 2019 Jun; 74(5):1010-1019.e6. PubMed ID: 30981630
[TBL] [Abstract][Full Text] [Related]
22. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
Wong M; Polly P; Liu T
Am J Cancer Res; 2015; 5(9):2823-37. PubMed ID: 26609488
[TBL] [Abstract][Full Text] [Related]
23. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
[TBL] [Abstract][Full Text] [Related]
24. Dot1-dependent histone H3K79 methylation promotes activation of the Mek1 meiotic checkpoint effector kinase by regulating the Hop1 adaptor.
Ontoso D; Acosta I; van Leeuwen F; Freire R; San-Segundo PA
PLoS Genet; 2013; 9(1):e1003262. PubMed ID: 23382701
[TBL] [Abstract][Full Text] [Related]
25. The many faces of histone H3K79 methylation.
Farooq Z; Banday S; Pandita TK; Altaf M
Mutat Res Rev Mutat Res; 2016; 768():46-52. PubMed ID: 27234562
[TBL] [Abstract][Full Text] [Related]
26. The emerging roles of DOT1L in leukemia and normal development.
McLean CM; Karemaker ID; van Leeuwen F
Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
[TBL] [Abstract][Full Text] [Related]
27. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
28. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
Spangler CJ; Yadav SP; Li D; Geil CN; Smith CB; Wang GG; Lee TH; McGinty RK
Cell Rep; 2022 Feb; 38(7):110369. PubMed ID: 35172132
[TBL] [Abstract][Full Text] [Related]
29. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
30. DOT1L O-GlcNAcylation promotes its protein stability and MLL-fusion leukemia cell proliferation.
Song T; Zou Q; Yan Y; Lv S; Li N; Zhao X; Ma X; Liu H; Tang B; Sun L
Cell Rep; 2021 Sep; 36(12):109739. PubMed ID: 34551297
[TBL] [Abstract][Full Text] [Related]
31. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases.
Wakeman TP; Wang Q; Feng J; Wang XF
EMBO J; 2012 May; 31(9):2169-81. PubMed ID: 22373577
[TBL] [Abstract][Full Text] [Related]
32. Dot1L mediated histone H3 lysine79 methylation is essential to meiosis progression in mouse oocytes.
Wang X; Gao W; Ma X; Wang X; Song C; Huang X; Liu H
Neuro Endocrinol Lett; 2014; 35(6):523-30. PubMed ID: 25433842
[TBL] [Abstract][Full Text] [Related]
33. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
34. The Role of DOT1L in Normal and Malignant Hematopoiesis.
Arnold O; Barbosa K; Deshpande AJ; Zhu N
Front Cell Dev Biol; 2022; 10():917125. PubMed ID: 35712672
[TBL] [Abstract][Full Text] [Related]
35. [DOT1: a distinct class of histone lysine methyltransferase].
Gao WL; Liu HL
Yi Chuan; 2007 Dec; 29(12):1449-54. PubMed ID: 18065378
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
Banday S; Farooq Z; Ganai SA; Altaf M
Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
[TBL] [Abstract][Full Text] [Related]
37. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract][Full Text] [Related]
38. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.
Chang MJ; Wu H; Achille NJ; Reisenauer MR; Chou CW; Zeleznik-Le NJ; Hemenway CS; Zhang W
Cancer Res; 2010 Dec; 70(24):10234-42. PubMed ID: 21159644
[TBL] [Abstract][Full Text] [Related]
39. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states.
Frederiks F; Tzouros M; Oudgenoeg G; van Welsem T; Fornerod M; Krijgsveld J; van Leeuwen F
Nat Struct Mol Biol; 2008 Jun; 15(6):550-7. PubMed ID: 18511943
[TBL] [Abstract][Full Text] [Related]
40. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
